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The use and potential commercial application of biosurfactants in the medical field has increased during
the past decade. Their antibacterial, antifungal and antiviral activities make them relevant molecules
for applications in combating many diseases and as therapeutic agents. In addition, their role as anti-
adhesive agents against several pathogens indicates their utility as suitable anti-adhesive coating agents
for medical insertional materials leading to a reduction in a large number of hospital infections without
the use of synthetic drugs and chemicals. This review looks at medicinal and therapeutic perspectives
on biosurfactant applications.
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Introduction
Microbial compounds that exhibit pronounced surface and emul-
sifying activities are classified as biosurfactants. Biosurfactants
comprise a wide range of chemical structures, such as glycol-
ipids, lipopeptides, polysaccharide–protein complexes, phosphol-
ipids, fatty acids and neutral lipids.1–5 For instance, Cooper and
Goldenberg6 described different bioemulsifiers produced by two
Bacillus species in water-soluble substrates with distinct emulsi-
fying and surface activities. It is, therefore, reasonable to expect
diverse properties and physiological functions for different
groups of biosurfactants. Moreover, these molecules can be tai-
lor-made to suit different applications by changing the growth
substrate or growth conditions.7 Although most biosurfactants are
considered to be secondary metabolites, some may play essential
roles for the survival of biosurfactant-producing microorganisms
through facilitating nutrient transport or microbe–host interac-
tions or by acting as biocide agents. Biosurfactant roles include
increasing the surface area and bioavailability of hydrophobic
water-insoluble substrates, heavy metal binding, bacterial patho-
genesis, quorum sensing and biofilm formation.8 Biosurfactants
are amphipathic molecules with both hydrophilic and hydro-
phobic moieties that partition preferentially at the interface
between fluid phases that have different degrees of polarity
and hydrogen bonding, such as oil and water or air and water
interfaces. This property explains their broad use in environ-
mental applications.9–11 Most work on biosurfactant applications
has been focused on their use in environmental applications
owing to their diversity, environmentally friendly nature, suitab-
ility for large-scale production and selectivity.12 Despite their
potential and biological origin only a few studies have been
carried out on applications related to the biomedical field.13–15
Some biosurfactants are suitable alternatives to synthetic medi-
cines and antimicrobial agents and may be used as safe and
effective therapeutic agents (Table 1).
Microbial surfactants have several advantages over chemical
surfactants such as lower toxicity, higher biodegradability and
effectiveness at extreme temperatures or pH values.16,17 Many of
the potential applications that have been considered for biosur-
factants depend on whether they can be produced economically;
however, much effort in process optimization and at the engin-
eering and biological levels has been carried out. Biosurfactant
production from inexpensive waste substrates, which decreases
their production cost,15,18 has been reported. In addition, legal
aspects such as stricter regulations concerning environmental
pollution by industrial activities and health regulations will
also strongly influence the chances of biodegradable biosurfact-
ants replacing their chemical counterparts.7
This review aims to cover the applications of various biosur-
factants in the medical field and also to provide an overview of
biosurfactant activities and mechanisms of interaction that could
be exploited further in developing alternative drugs, lines of
therapy or biomaterials.
Biosurfactants: mechanisms of interaction
Biosurfactants are microbial amphiphilic polymers and polyphilic
polymers that tend to interact with the phase boundary between
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two phases in a heterogeneous system, defined as the interface.
For all interfacial systems, it is known that organic molecules
from the aqueous phase tend to immobilize at the solid interface.
There they eventually form a film known as a conditioning film,
which will change the properties (wettability and surface energy)
of the original surface.19 In an analogy to organic conditioning
films, biosurfactants may interact with the interfaces and affect
the adhesion and detachment of bacteria. In addition, the sub-
stratum surface properties determine the composition and orienta-
tion of the molecules conditioning the surface during the first
hour of exposure. After about 4 h, a certain degree of uniformity
is reached and the composition of the adsorbed material becomes
substratum independent.20
Owing to the amphiphilic nature of biosurfactants, not only
hydrophobic but a range of interactions are involved in the pos-
sible adsorption of charged biosurfactants to interfaces. Most
natural interfaces have an overall negative or, rarely, positive
charge. Thus, the ionic conditions and the pH are important
parameters if interactions of ionic biosurfactants with interfaces
are to be investigated.21 Gottenbos et al.22 demonstrated that
positively charged biomaterial surfaces exert an antimicrobial
effect on adhering Gram-negative bacteria, but not on Gram-
positive bacteria. In addition, the molecular structure of a
surfactant will influence its behaviour at interfaces. In describing
the surface-active approach, an effort is made to elaborate on the
possible theoretical locations and orientations of the biosurfact-
ants. Nevertheless, it must be kept in mind that the situation in
natural systems is far more complex and requires the considera-
tion of many additional parameters.
Biological activity of biosurfactants
As described above, a broad range of chemical structures, such as
glycolipids, lipopeptides, polysaccharide–protein complexes,
phospholipids, fatty acids and neutral lipids, have been attributed
to biosurfactants.1,2,4,5 Some of these biosurfactants were
described for their potential to act as biologically active com-
pounds and applicability in the medical field.
Table 1. Examples of biosurfactant applications in the medical field
Microorganism Biosurfactant type Activity/application Reference(s)
Pseudomonas aeruginosa rhamnolipid * antimicrobial activity against Mycobacterium tuberculosis 51, 63, 76, 77
* anti-adhesive activity against several bacterial and yeast
strains isolated from voice prostheses
Bacillus subtilis surfactin * antimicrobial and antifungal activities 31, 33, 83–86
* inhibition of fibrin clot formation
* haemolysis and formation of ion channels in lipid membranes
* antitumour activity against Ehrlich’s ascite carcinoma cells
* antiviral activity against human immunodeficiency virus 1 (HIV-1)
Bacillus pumilus pumilacidin
(surfactin analogue)
* antiviral activity against herpes simplex virus 1 (HSV-1) 53
* inhibitory activity against H+, K+-ATPase and protection
against gastric ulcers in vivo
Bacillus subtilis iturin * antimicrobial activity and antifungal activity against
profound mycosis
5, 27–29, 88
* effect on the morphology and membrane structure of yeast cells
* increase in the electrical conductance of biomolecular
lipid membranes
* non-toxic and non-pyrogenic immunological adjuvant
Bacillus licheniformis lichenysin * antibacterial activity 78–81
* chelating properties that might explain the membrane-disrupting
effect of lipopeptides
Candida antartica mannosylerythritol
lipids
* antimicrobial, immunological and neurological properties 37–43
* induction of cell differentiation in the human promyelocytic
leukemia cell line HL60
* induction of neuronal differentiation in PC12 cells
Rhodococcus erythropolis treahalose lipid * antiviral activity against HSV and influenza virus 89, 90
Streptococcus thermophilus glycolipid * anti-adhesive activity against several bacterial and yeast strains
isolated from voice prostheses
26, 55, 74, 95, 96
Streptococcus mitis not identified * anti-adhesive activity against Streptococcus mutans 24, 25
Lactobacillus surlactin * anti-adhesive activity against several pathogens including
enteric bacteria
62, 97–100
Lactococcus lactis not identified * anti-adhesive activity against several bacterial and yeast
strains isolated from voice prostheses
55, 73
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Lipopeptides
Among the several categories of biosurfactants, lipopeptides are
particularly interesting because of their high surface activities and
antibiotic potential. Lipopeptides can act as antibiotics, antiviral
and antitumour agents, immunomodulators or specific toxins and
enzyme inhibitors. Ahimou et al.5 reported that lipopeptide pro-
file and bacterial hydrophobicity vary greatly with the strains,
iturin A being the only lipopeptide type produced by all Bacillus
subtilis strains. Surfactin was found to be more efficient than
iturin A in modifying the B. subtilis surface hydrophobic
character. This aspect appears essential, in association with the
antifungal properties of lipopeptides involved, in the biological
control of plant diseases. Morikawa et al.1 identified and char-
acterized a biosurfactant, arthrofactin, produced by Arthrobacter
species, which was found to be seven times more effective than
surfactin.
Iturin biosurfactants. Produced by the strains of B. subtilis, iturin
A is a potent antifungal lipopeptide with many properties, of
which antimicrobial activity was the first reported.5,27 Iturin
A’s mechanism of action is related to the disruption of the plasma
membrane by the formation of small vesicles and the aggregation
of intramembranous particles in yeast cells. Moreover, it also
significantly increases the electrical conductance of biomolecular
lipid membranes.28 Iturin A has been proposed as an effective
antifungal agent for profound mycosis.29 Other members of the
iturin group, including bacillomycin D and bacillomycin Lc, were
also found to have antimicrobial activity against Aspergillus
flavus, but the different lipid chain length apparently affected
the activity of the lipopeptide against other fungi.30 Thus, the
members of the iturin-like biosurfactant group have the potential
to be used as alternative potent antifungal agents.
Surfactin biosurfactants. Surfactin, a cyclic lipopeptide, is also
produced by B. subtilis strains and has well-known antimicrobial
properties.5 It has been reported to interact with artificial and
biomembrane systems, for example bacterial protoplasts and
enveloped viruses.31 There are three different types of surfactins,
A, B and C, which are classified according to the differences in
their amino acid sequences.
In addition to antifungal and antibacterial properties, surfactin
has also been related to several biological activities, namely the
inhibition of fibrin clot formation, the induction of ion channel
formation in lipid bilayer membranes, the inhibition of cyclic
adenosine monophosphate, the inhibition of platelet and spleen
cytosolic phospholipase A2 (PLA2), and antiviral and antitumour
activities.32 Kim et al.32 demonstrated that surfactin is a selective
inhibitor for cytosolic PLA2 and a putative anti-inflammatory
agent through the inhibitory effect produced by direct interaction
with cytosolic PLA2, and that inhibition of cytosolic PLA2 activ-
ity may suppress inflammatory responses. Vollenbroich et al.31
showed that surfactin treatment improved proliferation rates and
led to changes in the morphology of mammalian cells that had
been contaminated with mycoplasma. In addition, the low cyto-
toxicity of surfactin to mammalian cells permitted specific inac-
tivation of mycoplasmas without significant damaging effects on
cell metabolism and the proliferation rate of cells in culture. In
another study, the same authors33 showed that surfactin is active
against several viruses, including Semliki Forest virus, herpes
simplex virus (HSV), suid herpes virus, vesicular stomatitis
virus, simian immunodeficiency virus, feline calicivirus and mur-
ine encephalomyocarditis virus. The inactivation of enveloped
viruses, especially herpesviruses and retroviruses, was signific-
antly more efficient than that of non-enveloped viruses, suggest-
ing that the antiviral action of surfactin is primarily due to a
physicochemical interaction between the membrane-active sur-
factant and the outer part of the virus lipid membrane bilayer,
which causes permeability changes and at higher concentrations
leads finally to the disintegration of the mycoplasma membrane
system by a detergent effect.
Surfactin C was found to enhance the activation of prourok-
inase (plasminogen activator) and the conformational change
in plasminogen, leading to increased fibrinolysis in vitro and
in vivo.34 The plasminogen–plasmin system is involved in
blood clot dissolution as well as in a variety of physiological
and pathological processes requiring localized proteolysis. In a
rat pulmonary embolism model, surfactin C increased plasma clot
lysis when injected in combination with prourokinase.35 These
results point to the potential use of surfactin in thrombolytic
therapy related to pulmonary, myocardial and cerebral disorders.
Various nosocomial infections such as those related to the use
of central venous catheters, urinary catheters, prosthetic heart
valves, voice prostheses and orthopaedic devices are clearly asso-
ciated with biofilms that adhere to the biomaterial surface. These
infections share common characteristics even though the micro-
bial causes and host sites vary greatly. The most important of
these characteristics is that bacteria in biofilms evade host
defences and withstand antimicrobial chemotherapy. As antimi-
crobial resistance is nowadays a growing source of concern in
modern medicine, genetic engineering of the known biosurfactant
molecules is a key factor for the development of alternative
prophylactic and therapeutic agents. Symmank et al.36 produced
a novel lipohexapeptide with altered antimicrobial activities by
genetic engineering of the surfactin biosynthesis mechanism.
Reduced detectable haemolytic activity concomitant with an
increase in growth inhibition of bacterial cells, including Bacillus
licheniformis, was observed. Thus, similar surfactin derivatives
may exhibit reduced toxicity against eukaryotic cells, which
could improve their therapeutic applications.
Glycolipids
Glycolipids are the most common class of biosurfactants, of
which the most effective from the point of view of surface-active
properties are the trehalose lipids obtained from Mycobacterium
and related bacteria, the rhamnolipids obtained from Pseudomo-
nas species and the sophorolipids obtained from yeasts. Otto
et al.18 described the production of sophorose lipids (SLs)
using deproteinized whey concentrate as the substrate by a
two-stage process. Several antimicrobial, immunological and
neurological properties have been attributed to mannosyleryth-
ritol lipid (MEL), a yeast glycolipid biosurfactant produced from
vegetable oils by Candida strains. Kitamoto et al.37 showed
that MEL exhibits antimicrobial activity, particularly against
Gram-positive bacteria. Isoda et al.38 investigated the biological
activities of seven extracellular microbial glycolipids, including
MEL-A, MEL-B, polyol lipid, rhamnolipid, SL and succinoyl-
trehalose lipids STL-1 and STL-3. Except for rhamnolipid, all
the other glycolipids tested induced cell differentiation instead of
cell proliferation in the human promyelocytic leukaemia cell
line HL60. STL and MEL differentiation-inducing activity was
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attributed to a specific interaction with the plasma membrane
instead of a simple detergent-like effect.
In addition, the effects of several kinds of microbial
extracellular glycolipids on neurite initiation in PC12 cells
were investigated.39 The PC12 cell line, derived from a rat pheo-
chromocytoma, provides a relatively simple, and homogeneous,
system for studying various aspects of neuronal differentiation,
because PC12 cells can survive and proliferate without requiring
the presence of neutrotrophic factors. A significant neurite out-
growth was observed as a consequence of the addition of MEL-A,
MEL-B and SL to PC12 cells. MEL-A increased acetylcholin-
esterase activity to an extent similar to nerve growth factor (NGF).
MEL-A induced neurite outgrowth after treatment of PC12 cells
with an anti-NGF receptor antibody that obstructed the NGF
action. It was shown that MEL-A and NGF induce differentiation
of PC12 cells through different mechanisms. Moreover, MEL
was found to induce the outgrowth of neurites, enhance the
activity of acetylcholinesterase and increase the levels of galacto-
sylceramide from PC12 pheochromocytoma cells.40
Glycolipids have also been implicated in growth arrest, apop-
tosis and the differentiation of mouse malignant melanoma
cells.41,42 Exposure of B16 cells to MEL resulted in the con-
densation of the chromatin, DNA fragmentation and sub-G1
arrest (the sequence of events of apoptosis). In addition MEL
was also reported to markedly inhibit the growth of mouse melan-
oma B16 cells in a dose-dependent manner. Moreover, MEL
exposure stimulated the expression of differentiation markers
of melanoma cells, such as tyrosinase activity and the enhanced
production of melanin, which is an indication that MEL triggered
both apoptotic and cell differentiation mechanisms. In addition,
exposure of PC12 cells to MEL enhanced the activity of acetyl-
cholinesterase and interrupted the cell cycle at the G1 phase, with
resulting outgrowth of neurites and partial cellular differenti-
ation.43 MEL has been implicated in the induction of neuronal
differentiation in PC12 cells and therefore provides the basis for
the use of glycolipids as therapeutic agents for treatment of
cancer cells. Nevertheless, further studies on the molecular
basis of the signalling cascade that follows exposure of PC12
cells to MEL may ultimately lead to a better understanding of
the processes that result in the outgrowth of neurites and the
commitment to differentiation of PC12 cells.
In other studies four analogues of STL-3 at their critical
micelle concentration were evaluated for their ability to inhibit
growth and induce differentiation of HL60 human promyelocytic
leukaemia cells.44 It was found that the effect of STL-3 and its
analogues on HL60 cells was dependent on the hydrophobic
moiety of STL-3. Furthermore, a high binding affinity of
MEL towards human immunoglobulin G (HIgG) was shown
by Im et al.45 They suggested the possibility of using MEL-A
as an alternative ligand for immunoglobulins. In subsequent stud-
ies they evaluated MEL-A, MEL-B and MEL-C attached to
PHEMA beads [where PHEMA stands for poly(2-hydroxyethyl
methacrylate)] for their binding affinity to HIgG.46 Of these three
composite compounds, those bearing MEL-A exhibited the high-
est binding capacity for HIgG. More significantly, the bound
HIgG was efficiently recovered (90%) under significantly
mild elution conditions, with phosphate buffer at pH 7, indicating
a great potential of the glycolipids as an affinity ligand material.
Inoh et al.47,48 reported that MEL-A significantly increased the
efficiency of gene transfection mediated by cationic liposomes
with a cationic cholesterol derivative. Among the cationic lipo-
somes tested, the liposomes bearing cholesteryl-3b-carboxya-
mindoethylene-N-hydroxyethylamine and MEL-A showed the
best efficiency for delivery of plasmids encoding luciferase
(pGL3) into the target cells (NIH3T3, COS-7 and HeLa). The
properties, production and applications of MEL were widely
studied by Kitamoto et al.,49 particularly the exceptional inter-
facial properties and differentiation-inducing activities of MEL.
They also focused on the excellent biological and self-assembling
actions of MEL and examined the effect of MEL-A on gene
transfection using cationic liposomes.
Other biosurfactants with biological activity
Nielsen et al.50 reported viscosinamide, a cyclic depsipeptide, to
be a new antifungal surface-active agent produced by Pseudo-
monas fluorescens, with different properties compared with the
biosurfactant viscosin, known to be produced from the same
species and shown to have antibiotic activity.23 Massetolides
A–H, also cyclic depsipeptides, were isolated from the Pseudo-
monas species, derived from a marine habitat, and found to
exhibit in vitro antimicrobial activity against Mycobacterium
tuberculosis and Mycobacterium avium-intracellulare.51
Precursors and degeneration products of sphingolipid biosur-
factants were found to inhibit the interaction of Streptococcus
mitis with buccal epithelial cells and of Staphylococcus aureus
with nasal mucosal cells.52 Gram-positive Bacillus pumilis cells
were found to produce pumilacidin A, B, C, D, E, F and G, which
exhibited antiviral activity against HSV-1 and inhibitory activity
against H+, K+-ATPase, and were found to be protective against
gastric ulcers,53 probably through the inhibition of microbial
activity contributing to these ulcers.
Antimicrobial activity of biosurfactants
The antimicrobial activity of several biosurfactants has been
reported in the literature for many different applications.54 For
instance, the antimicrobial activity of two biosurfactants obtained
from probiotic bacteria, Lactococcus lactis 53 and Streptococcus
thermophilus A, against a variety of bacterial and yeast strains
isolated from explanted voice prostheses was evaluated, as shown
in Table 2.55 We found that both biosurfactants have a high
antimicrobial activity even at low concentrations against Candida
tropicalis GB 9/9, one of the strains held responsible for pros-
theses failure. At the highest concentration tested both biosur-
factants were active against all the bacterial and yeast strains
studied. In another study, Reid et al.56,57 emphasized a possible
probiotic role for the biosurfactant-producing lactobacilli in the
restoration and maintenance of healthy urogenital and intestinal
tracts, conferring protection against pathogens, and suggested a
reliable alternative treatment and preventive regimen to antibiot-
ics in the future. The first clinical evidence that probiotic lacto-
bacilli can be delivered to the vagina following oral intake was
provided by Reid et al.57 and, although only a limited set of
strains have any proven clinical effect or scientific basis, there
are sufficient data to suggest that this approach could provide a
valuable alternative to antibiotic prophylaxis and treatment of
infection. By the use of a rat model of surgical implant infection,
Gan et al.58 determined that the probiotic strain, Lactobacillus
fermentum RC-14, and its secreted biosurfactant reduced infec-
tions associated with surgical implants, which are mainly
caused by S. aureus through inhibition of growth and reduction
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of adherence to surgical implants. A recent in vitro study of
Lactobacillus plantarum 299v and Lactobacillus rhamnosus
GG showed that these probiotic strains could inhibit the adhesion
of Escherichia coli to intestinal epithelial cells by stimulating
epithelial expression of mucins.59 These strains, however, were
also found to be biosurfactant producers.60 These observations
generally indicated that biosurfactants might also contain signal-
ling factors that interact with the host and/or bacterial cells,
leading to the inhibition of infections. Moreover, they support
the assertion of a possible role in preventing microbial adhe-
sion61,62 and their potential in developing anti-adhesion biolo-
gical coatings for implant materials.63
Antibacterial and antiphytoviral effects of various rhamno-
lipids have been described in the literature.13,64 Seven different
rhamnolipids were identified in cultures of Pseudomonas aeru-
ginosa AT10 from soybean oil refinery wastes and these showed
excellent antifungal properties against various fungi.65 Golubev
et al.66 reported the production of an extracellular, low molecular
weight, protease-resistant thermostable glycolipid fungicide from
the yeast Pseudozyma fusiformata (Ustilaginales). This fungicide
was active against >80% of the 280 yeast and yeast-like species
tested under acidic conditions (pH 4.0) at 20–30C.67 The puri-
fied glycolipids enhanced non-specific permeability of the cyto-
plasmic membrane in sensitive cells, which resulted in ATP
leakage.
Anti-adhesive activity of biosurfactants
Biosurfactants have been found to inhibit the adhesion of patho-
genic organisms to solid surfaces or to infection sites; thus, prior
adhesion of biosurfactants to solid surfaces might constitute a
new and effective means of combating colonization by patho-
genic microorganisms.8 Pre-coating vinyl urethral catheters by
running the surfactin solution through them before inoculation
with media resulted in a decrease in the amount of biofilm
formed by Salmonella typhimurium, Salmonella enterica, E. coli
and Proteus mirabilis.68 Given the importance of opportunistic
infections with Salmonella species, including urinary tract
infections of AIDS patients, these results have great potential
for practical applications. In addition, the use of lactobacilli as
a probiotic for the prevention of urogenital infections has been
widely studied. The role of Lactobacillus species in the female
urogenital tract as a barrier to infection is of considerable inter-
est.69 These organisms are believed to contribute to the control of
vaginal microbiota by competing with other microorganisms for
adherence to epithelial cells and by producing biosurfactants.
There are reports of inhibition of biofilm formation by uropatho-
gens and yeast on silicone rubber with biosurfactants produced by
Lactobacillus acidophilus.70,71 Heinemann et al.72 showed that
L. fermentum RC-14 releases surface-active components that can
inhibit adhesion of uropathogenic bacteria, including Entero-
coccus faecalis. Efforts in the development of strategies to pre-
vent the microbial colonization of silicone rubber voice
prostheses have been reported by Rodrigues et al.73,74 The ability
of biosurfactants obtained from the probiotic strains, L. lactis 53
and S. thermophilus A, to inhibit adhesion of four bacterial and
two yeast strains isolated from explanted voice prostheses to
pre-coated silicone rubber was evaluated. The results obtained
showed that the biosurfactants were effective in decreasing
the initial deposition rates, as well as the number of bacterial
cells adhering after 4 h, for all microorganisms tested. Over
90% reductions in the initial deposition rates were achieved
for most of the bacterial strains tested. The biosurfactant
Table 2. Antimicrobial activity of biosurfactants (at different concentrations) against several bacterial and yeast strains isolated from
explanted voice prostheses
Biosurfactant obtained from L. lactis 53
Microorganism 5 mg/mL 10 mg/mL 25 mg/mL 50 mg/mL 100 mg/mL
Staphylococcus epidermidis GB 9/6 – – + + +
Streptococcus salivarius GB 24/9 – – – – +
Staphylococcus aureus GB 2/1 – – – + +
Rothia dentocariosa GBJ 52/2B – – – – –
Candida albicans GBJ 13/4A – – – + +
Candida tropicalis GB 9/9
+ + + + +
Biosurfactant obtained from S. thermophilus A
Microorganism 3 mg/mL 5 mg/mL 10 mg/mL 50 mg/mL 100 mg/mL
Staphylococcus epidermidis GB 9/6 – – – + +
Streptococcus salivarius GB 24/9 – – – – +
Staphylococcus aureus GB 2/1 – – – – +
Rothia dentocariosa GBJ 52/2B – – – – –
Candida albicans GBJ 13/4A – – – + +
Candida tropicalis GB 9/9 + + + + +
The experiments were scored as positive (+) when growth inhibition was observed (no colonies formed); a– sign indicates that some colonies formed within the zones;
and no growth inhibition was marked as negative (–). For details see Rodrigues et al.55
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obtained from S. thermophilus A was more effective against
Rothia dentocariosa GBJ 52/2B, which is one of the strains
responsible for valve prosthesis failure. The initial deposition
rates of the yeast strains were far less reduced in the presence
of the biosurfactant than the other tested strains. Recently the
authors also demonstrated that when rinsing flow chambers,
designed to monitor microbial adhesion, with a rhamnolipid bio-
surfactant-containing solution the rate of deposition and adhesion
was significantly reduced for a variety of bacterial and yeast
strains isolated from explanted voice prostheses to silicone rub-
ber, as shown in Table 3.63 Therefore, we believe that this rham-
nolipid may be useful as a biodetergent solution for prostheses
cleaning, prolonging their lifetime and directly benefiting laryn-
gectomized patients.
The role of surfactants in defence against infection and inflam-
mation in the human body is a well-known phenomenon. The
pulmonary surfactant is a lipoprotein complex synthesized and
secreted by the epithelial lung cells into the extracellular space,
where it lowers the surface tension at the air–liquid interface of
the lung and represents a key factor against infections and inflam-
matory lung diseases.75
Biomedical and therapeutic applications of
biosurfactants
Some biosurfactants are a suitable alternative to synthetic medi-
cines and antimicrobial agents and may be used as safe and
effective therapeutic agents.8,12 There has been increasing interest
in the effect of biosurfactants on human and animal cells and cell
lines.
MELs produced by Candida antartica,37 rhamnolipids pro-
duced by P. aeruginosa76,77 and lipopeptides produced by B.
subtilis31 and B. licheniformis7,78–80 have been shown to have
antimicrobial activities. Jenny et al.78 determined the structure
and characterized surface activities of biosurfactants produced by
B. licheniformis, while Lin et al.79 described their continuous
production. Yakimov et al.80 demonstrated the antibacterial activ-
ity of lichenysin A, a biosurfactant produced by B. licheniformis
that compares favourably with other surfactants. More recently,
Grangemard et al.81 reported the chelating properties of licheny-
sin, which might explain the membrane-disrupting effect of lipo-
peptides. In another study, Carrillo et al.82 noted a molecular
mechanism of membrane permeabilization by surfactin, which
may explain surfactin-induced pore formation underlying the
antibiotic and haemolytic action of these lipopeptides. This
study also suggested that the membrane barrier properties are
likely to be damaged in the areas where surfactin oligomers
interact with the phospholipids, at concentrations much below
the onset for solubilization. Such properties can cause structural
fluctuations that may well be the primary mode of the antibiotic
action of this lipopeptide. Surfactin-type peptides that can rapidly
act on membrane integrity rather than other vital cellular pro-
cesses may perhaps constitute the next generation of antibiotics.
Lipopeptide surfactin was also reported to have an antitumour
activity against Ehrlich’s ascite carcinoma cells83 and an anti-
fungal activity as well as various pharmacological applications
such as inhibiting fibrin clot formation and haemolysis84 and
formation of membrane ion channels.85 In addition, surfactin
and surfactin analogues have been reported as antiviral agents:
a significant inhibitory effect of pumilacidin on HSV-1 was
demonstrated53 as well as an inhibitory activity against H+, K+-
ATPase and protection against gastric ulcers in vivo. The poten-
tial of surfactin against human immunodeficiency virus 1 (HIV-1)
was reported by Itokawa et al.86 The antiviral action of surfactin
was suggested to be due to physicochemical interactions between
the membrane-active surfactant and the virus lipid membrane.33
Another lipopeptide, iturin, produced by B. subtilis was repor-
ted to have antifungal properties,28 affecting the morphology and
membrane structure of yeast cells. Iturin was shown to pass
through the cell wall and disrupt the plasma membrane with
the formation of small vesicles and the aggregation of intramem-
branous particles. Iturin also passes through the plasma mem-
brane and interacts with the nuclear membrane and probably with
membranes of other cytoplasmic organelles.
Possible applications of biosurfactants as emulsifying agents
for drug transport to the infection site, as agents supplementing
the pulmonary surfactant and as adjuvants for vaccines were
suggested by Kosaric.87
Mittenbuhler et al.88 showed that bacterial lipopeptides con-
stitute potent non-toxic and non-pyrogenic immunological
adjuvants when mixed with conventional antigens. A marked
enhancement of the humoral immune response was obtained
with the low molecular mass antigens iturin AL, herbicolin A
and microcystin (MLR) coupled to poly-L-lysine (MLR–PLL) in
rabbits and in chickens. Conjugates of lipopeptide–Th-cell epi-
topes also constituted effective adjuvants for the in vitro immun-
ization of either human mononuclear cells or mouse B cells with
MLR–PLL and resulted in a significantly increased yield of anti-
body-secreting hybridomas.
The biological activities of MELs obtained from C. antartica
were investigated by Isoda et al.38 and an induction of cell dif-
ferentiation in the human promyelocytic leukaemia cell line
HL60 was reported. These glycolipids induced the human myelo-
genous leukaemia cell line K562 and the human basophilic
leukaemia cell line Ku812 to differentiate into monocytes,
granulocytes and megakaryocytes. The succinoyl-trehalose
lipid produced by Rhodococcus erythropolis has also been repor-
ted to inhibit HSV and influenza virus.89,90 The deficiency of
pulmonary surfactant described earlier which is responsible for
Table 3. Desorption percentages of microorganisms isolated from
explanted voice prostheses adhered to silicone rubber as a result of
rhamnolipid perfusion through the parallel-plate flow chamber
with and without a following passage of a liquid–air interface
Desorption percentages (%)
Microorganism
rinsing with
rhamnolipid
solution
passage
air–liquid
interface
Staphylococcus epidermidis GB 9/6 80.2 89.5
Streptococcus salivarius GB 24/9 87.3 98.7
Staphylococcus aureus GB 2/1 21.0 67.4
Rothia dentocariosa GBJ 52/2B 63.3 98.9
Candida albicans GBJ 13/4A 81.8 95.5
Candida tropicalis GB 9/9 74.2 95.5
Results are averages of duplicate experiments varying within 10–15%. For
details see Rodrigues et al.63
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respiration failure in premature infants75 may be corrected
through the isolation of genes for protein molecules of this
surfactant and cloning in bacteria for possible fermentative
production and use in medical application.76 Sano et al.91 demon-
strated the different actions of the pulmonary surfactant protein A
upon distinct serotypes of lipopolysaccharide, which is the major
constituent of the outer membrane of Gram-negative bacteria.
Although there is an increasing potential for the application of
biosurfactants in the biomedical field, some of these molecules
may pose a risk for humans. For instance, P. aeruginosa is a
bacterium responsible for severe nosocomial infections, life-
threatening infections in immunocompromised persons and
chronic infections in cystic fibrosis patients; thus, rhamnolipids
have to be well investigated prior to such uses. The virulence of a
P. aeruginosa strain depends on a large number of cell-associated
and extracellular factors.92–94 Cell-to-cell signalling systems con-
trol the expression and allow a coordinated, cell-density-depend-
ent production of many extracellular virulence factors. The
possible role of cell-to-cell signalling in the pathogenesis of
P. aeruginosa infections and a rationale for targeting cell-to-
cell signalling systems in the development of new therapeutic
approaches were discussed by Van Delden and Iglewski.92 Syn-
thesis of rhamnolipids is regulated by a very complex genetic
regulatory system that also controls different P. aeruginosa viru-
lence-associated traits.77 The cosmetic and healthcare industries
use large amounts of surfactants for a wide variety of products,
including insect repellents, antacids, acne pads, contact lens
solutions, hair colour and care products, deodorants, nail care
products, lipstick, eye shadow, mascara, toothpaste, denture
cleaners, lubricated condoms, baby products, foot care products,
antiseptics and shaving and depilatory products.16 Biosurfactants
are known to have advantages over synthetic surfactants such
as low irritancy or anti-irritating effects and compatibility with
skin. Rhamnolipids in particular are being used as cosmetic
additives and have been patented to make some liposomes and
emulsions,93,94 both of which are important in the cosmetic
industry.
Another approach to the use of biosurfactants in biomedical
applications is the development of suitable anti-adhesion biolo-
gical coatings for implant materials. Dairy S. thermophilus strains
produced a biosurfactant which caused its own desorption from
glass, leaving a completely non-adhesive coating.26 Busscher
et al.95,96 also showed that biosurfactant release by S. thermo-
philus inhibited adhesion on to silicone rubber and growth of
several bacterial and yeast strains isolated from explanted voice
prostheses. Rodrigues et al.,73 using an artificial throat model,
showed that biosurfactants obtained from probiotic strains greatly
reduced microbial numbers on voice prostheses and also induced
a decrease in the airflow resistance of voice prostheses after
biofilm formation, which may constitute a mechanism by
which the lifetime of indwelling silicone rubber voice prostheses
can be prolonged. A role for biosurfactants as defence weapons in
post-adhesion competition with other strains or species has to
date been suggested only for biosurfactants released by S. mitis
strains against Streptococcus mutans adhesion24,25 and for bios-
urfactants released by lactobacilli against adhesion of uropatho-
gens.97,98 The biosurfactant surlactin,99 produced by several
Lactobacillus isolates, was suggested as a suitable anti-adhesive
coating for catheter materials. Velraeds et al.100 also reported on
the inhibition of adhesion of pathogenic enteric bacteria by a
biosurfactant produced by a Lactobacillus strain and later showed
that the biosurfactant caused an important dose-related inhibition
of the initial deposition rate of E. coli and other bacteria adherent
on both hydrophobic and hydrophilic substrata.62
Conclusions
A host of interesting features of biosurfactants have led to a wide
range of potential applications in the medical field. They are
useful as antibacterial, antifungal and antiviral agents, and
they also have the potential for use as major immunomodulatory
molecules and adhesive agents and in vaccines and gene therapy.
Biosurfactants have been used for gene transfection, as ligands
for binding immunoglobulins, as adjuvants for antigens and also
as inhibitors for fibrin clot formation and activators of fibrin clot
lysis. Promising alternatives to produce potent biosurfactants with
altered antimicrobial profiles and decreased toxicity against
mammalian cells may be exploited by genetic alteration of bios-
urfactants. Furthermore, biosurfactants have the potential to be
used as anti-adhesive biological coatings for medical insertional
materials, thus reducing hospital infections and use of synthetic
drugs and chemicals. They may also be incorporated into probi-
otic preparations to combat urogenital tract infections and pul-
monary immunotherapy.
In spite of the immense potential of biosurfactants in this field,
their use still remains limited, possibly due to their high produc-
tion and extraction cost and lack of information on their toxicity
towards human systems. Further investigations on human cells
and natural microbiota are needed to validate the use of biosur-
factants in several biomedical and health-related areas. Never-
theless, there appears to be great potential for their use in the
medical science arena waiting to be fully exploited.
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